Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD

医学 拜瑞妥 阿司匹林 血运重建 外科 危险系数 心肌梗塞 氯吡格雷 临床终点 冲程(发动机) 溶栓 截肢 内科学 随机对照试验 心脏病学 华法林 心房颤动 置信区间 工程类 机械工程
作者
Jennifer A. Rymer,Sonia S. Anand,E. Sebastian Debus,Lloyd Haskell,Connie N. Hess,W. Schuyler Jones,Eva Muehlhofer,Scott D. Berkowitz,Rupert Bauersachs,Marc P. Bonaca,Manesh R. Patel
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:148 (24): 1919-1928 被引量:10
标识
DOI:10.1161/circulationaha.122.063806
摘要

BACKGROUND: Rivaroxaban plus aspirin compared with aspirin alone reduced major cardiac and ischemic limb events after lower extremity revascularization (LER) in the VOYAGER PAD (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) trial. The effect has not been described in patients undergoing endovascular LER. METHODS: The VOYAGER PAD trial randomized 6564 patients with symptomatic peripheral artery disease to a double-blinded treatment with 2.5 mg of rivaroxaban BID or matching placebo and 100 mg of aspirin daily. The primary efficacy outcome was a composite of acute limb ischemia, major amputation of a vascular pathogenesis, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety end point was Thrombolysis in Myocardial Infarction major bleeding. A prespecified subgroup of patients who underwent endovascular revascularization was included. RESULTS: Endovascular LER occurred in 4379 (66.7%) patients and surgical LER in 2185 (33.3%). Over a 3-year follow-up, rivaroxaban reduced the risk of the primary outcome by 15% (hazard ratio [HR], 0.85 [95% CI, 0.76–0.96]) with an absolute risk reduction of 0.92% at 6 months and 1.04% at 3 years and a consistent benefit in those receiving endovascular (HR, 0.89 [95% CI, 0.76–1.03]) or surgical LER (HR, 0.81 [95% CI, 0.67–0.98]; P interaction=0.43). For endovascular-treated patients, rivaroxaban reduced the risk of acute limb ischemia or major amputation of a vascular pathogenesis by 30% (HR, 0.70 [95% CI, 0.54–0.90]; P =0.005) with an absolute risk reduction of 1.0% at 6 months and 2.0% at 3 years compared with aspirin alone. Among endovascular-treated patients, the median duration of concomitant dual antiplatelet therapy with clopidogrel treatment was 31 days (interquartile range, 30–58). There was a consistent benefit for rivaroxaban regardless of background clopidogrel. Thrombolysis in Myocardial Infarction major bleeding was significantly higher for the rivaroxaban and aspirin group for the endovascular cohort (HR, 1.66 [95% CI, 1.06–2.59]) with an absolute risk increase of 0.9% at 3 years with no increase in intracranial or fatal bleeding observed (HR, 0.86 [95% CI, 0.40–1.87]; P =0.71). Mortality with rivaroxaban was higher in the endovascular-treated patients (HR, 1.24 [95% CI, 1.02–1.52]), although this finding was isolated to specific regions. CONCLUSIONS: Rivaroxaban added to aspirin or dual antiplatelet therapy after LER for peripheral artery disease reduces ischemic risk and increases major bleeding without an increased risk of intracranial or fatal bleeding. These benefits are consistent in those treated with endovascular and surgical approaches with significant benefits for major adverse limb events. These data support the use of rivaroxaban in addition to aspirin or dual antiplatelet therapy after endovascular intervention for symptomatic peripheral artery disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张宁波完成签到,获得积分0
1秒前
sue完成签到,获得积分10
2秒前
3秒前
慕青应助害羞的山柏采纳,获得10
4秒前
平常的可乐完成签到 ,获得积分10
6秒前
深情安青应助momo采纳,获得10
7秒前
852应助王汉韬采纳,获得10
7秒前
Anmaterchem1完成签到,获得积分10
8秒前
潘善若发布了新的文献求助10
8秒前
西西完成签到,获得积分10
11秒前
乐乐应助潘善若采纳,获得10
13秒前
14秒前
量子星尘发布了新的文献求助10
14秒前
小小完成签到,获得积分10
14秒前
西瓜汁完成签到,获得积分10
15秒前
向日葵完成签到,获得积分10
16秒前
16秒前
17秒前
17秒前
17秒前
18秒前
王汉韬发布了新的文献求助10
19秒前
19秒前
21秒前
鸢也完成签到,获得积分10
21秒前
22秒前
110发布了新的文献求助10
23秒前
24秒前
露露发布了新的文献求助10
24秒前
坚定路人完成签到,获得积分10
25秒前
潘善若发布了新的文献求助10
26秒前
SciGPT应助沈清酌采纳,获得10
27秒前
28秒前
28秒前
29秒前
30秒前
科研通AI2S应助科研通管家采纳,获得10
32秒前
天天快乐应助科研通管家采纳,获得10
32秒前
英俊的铭应助科研通管家采纳,获得10
32秒前
英俊的铭应助科研通管家采纳,获得10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158